Mer receptor tyrosine kinase is a therapeutic target in pre-B-cell acute lymphoblastic leukemia.

  title={Mer receptor tyrosine kinase is a therapeutic target in pre-B-cell acute lymphoblastic leukemia.},
  author={Rachel M. A. Linger and Alisa B. Lee-Sherick and Deborah Deryckere and Rebecca A. Cohen and Kristen M. Jacobsen and Amy McGranahan and Lu{\'i}s T. A. N. Brand{\~a}o and Amanda Winges and Kelly K. Sawczyn and Xiayuan Liang and Amy K. Keating and Aik Choon Tan and H. Shelton Earp and Douglas K. Graham},
  volume={122 9},
Acute lymphoblastic leukemia (ALL) is currently treated with an intense regimen of chemotherapy yielding cure rates near 85%. However, alterations to treatment strategies using available drugs are unlikely to provide significant improvement in survival or decrease therapy-associated toxicities. Here, we report ectopic expression of the Mer receptor tyrosine kinase in pre-B-cell ALL (B-ALL) cell lines and pediatric patient samples. Inhibition of Mer in B-ALL cell lines decreased activation of… CONTINUE READING
Highly Cited
This paper has 35 citations. REVIEW CITATIONS


Publications citing this paper.
Showing 1-10 of 18 extracted citations

The proto-oncogene Mer tyrosine kinase is a novel therapeutic target in mantle cell lymphoma

Journal of hematology & oncology • 2018
View 6 Excerpts
Highly Influenced


Publications referenced by this paper.
Showing 1-10 of 40 references

Targeting FLT3 for the treatment of leukemia.

Seminars in hematology • 2008
View 11 Excerpts
Highly Influenced

Flow cytometry analysis of murine hematopoietic stem cells.

Cytometry. Part A : the journal of the International Society for Analytical Cytology • 2013
View 1 Excerpt

Similar Papers

Loading similar papers…